Bioretec announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through Payment (TPT) status for the company’s RemeOs Screw LAG Solid, effective October 1, 2025.
“Building on the success of Breakthrough Device Designation and FDA De Novo grant, securing CMS TPT approval represents a remarkable milestone,” said Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec. “This recognition of the value of our innovative product and the support to accelerate its adoption in the US, further empowers hospitals, surgery centers, and surgeons to utilize RemeOs, the first-of-its-kind fixation technology that supports natural healing.”
The approval is reflected in the October 2025 Healthcare Common Procedure Coding System (HCPCS) quarterly update, which establishes a new billing code, C1741, for absorbable anchor/screw implants. This designation makes RemeOs eligible for separate pass-through payment under both the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment system, providing incremental reimbursement for Medicare patients.
RemeOs is the first and only osteopromotive absorbable metal implant for orthopedic use in the U.S. Made from a proprietary magnesium alloy, RemeOs provides strong and stable fixation during healing and gradually degrades as it is replaced by bone, reducing the risks and costs associated with permanent implants and subsequent hardware removal surgeries.
In March 2023, the RemeOs Screw LAG Solid received FDA De Novo market authorization, confirming its status as a novel technology in orthopedic fixation.
Bioretec announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through Payment (TPT) status for the company's RemeOs Screw LAG Solid, effective October 1, 2025.
"Building on the success of Breakthrough Device Designation and FDA De Novo grant, securing CMS TPT approval represents a remarkable...
Bioretec announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through Payment (TPT) status for the company’s RemeOs Screw LAG Solid, effective October 1, 2025.
“Building on the success of Breakthrough Device Designation and FDA De Novo grant, securing CMS TPT approval represents a remarkable milestone,” said Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec. “This recognition of the value of our innovative product and the support to accelerate its adoption in the US, further empowers hospitals, surgery centers, and surgeons to utilize RemeOs, the first-of-its-kind fixation technology that supports natural healing.”
The approval is reflected in the October 2025 Healthcare Common Procedure Coding System (HCPCS) quarterly update, which establishes a new billing code, C1741, for absorbable anchor/screw implants. This designation makes RemeOs eligible for separate pass-through payment under both the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment system, providing incremental reimbursement for Medicare patients.
RemeOs is the first and only osteopromotive absorbable metal implant for orthopedic use in the U.S. Made from a proprietary magnesium alloy, RemeOs provides strong and stable fixation during healing and gradually degrades as it is replaced by bone, reducing the risks and costs associated with permanent implants and subsequent hardware removal surgeries.
In March 2023, the RemeOs Screw LAG Solid received FDA De Novo market authorization, confirming its status as a novel technology in orthopedic fixation.
Copy to clipboard 
